Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: "in situ proteomics," or just a "stain"?

@article{Taylor2014PredictiveBA,
  title={Predictive biomarkers and companion diagnostics. The future of immunohistochemistry: "in situ proteomics," or just a "stain"?},
  author={Clive R. Taylor},
  journal={Applied immunohistochemistry & molecular morphology : AIMM},
  year={2014},
  volume={22 8},
  pages={555-61}
}
INTRODUCTION: DEFINITIONS Predictive biomarkers are so named because the level of expression in a tumor may be of value in predicting the effectiveness of a particular “targeted” therapy for that specified tumor. A “companion diagnostic” is a test or assay that detects a predictive biomarker, thereby allowing classification of patients (tumors) into responders and nonresponders, for the corresponding therapeutic agent. The terms “companion diagnostic,” “predictive diagnostic,” “precision… CONTINUE READING